clinical trial · NCT04952779
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Novo Nordisk A/S·—·completed·n = 750
Diabetes Mellitus, Type 2Xultophy® (insulin degludec/liraglutide)
brief summary
The aim of this study is to assess the safety and effectiveness of Xultophy® initiated according to label in adults with type 2 diabetes mellitus (T2DM) under routine clinical practice conditions. Participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26 weeks.
started
Jun 2, 2021
primary completion
Dec 15, 2024
completion
Dec 15, 2024
last updated
Dec 31, 2025
official title
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec / Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol